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and correlates with airflow limitation
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Background: COPD is a progressive disease of the airways that is characterized by neutrophilic inflammation, a
condition known to promote the excessive formation of neutrophil extracellular traps (NETs). The presence of large
amounts of NETs has recently been demonstrated for a variety of inflammatory lung diseases including cystic
fibrosis, asthma and exacerbated COPD.
Objective: We test whether excessive NET generation is restricted to exacerbation of COPD or whether it also
occurs during stable periods of the disease, and whether NET presence and amount correlates with the severity of
airflow limitation.
Patients, materials and methods: Sputum samples from four study groups were examined: COPD patients during
acute exacerbation, patients with stable disease, and smoking and non-smoking controls without airflow limitation.
Sputum induction followed the ECLIPSE protocol. Confocal laser microscopy (CLSM) and electron microscopy were
used to analyse samples. Immunolabelling and fluorescent DNA staining were applied to trace NETs and related
marker proteins. CLSM specimens served for quantitative evaluation.
Results: Sputum of COPD patients is clearly characterised by NETs and NET-forming neutrophils. The presence of
large amounts of NET is associated with disease severity (p < 0.001): over 90 % in exacerbated COPD, 45 % in stable
COPD, and 25 % in smoking controls, but less than 5 % in non-smokers. Quantification of NET-covered areas in
sputum preparations confirms these results.
Conclusions: NET formation is not confined to exacerbation but also present in stable COPD and correlates with
the severity of airflow limitation. We infer that NETs are a major contributor to chronic inflammatory and lung tissue
damage in COPD.
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Chronic obstructive pulmonary disease (COPD) is usu-
ally a progressive neutrophilic inflammatory airway dis-
order following long-term exposure to external stresses,
such as inhaled tobacco smoke. Periods of stable condi-
tion alternate with severe episodes of worsening (exacer-
bations), leading to increasing impairment of lung
function. Such lung function decline provides the basis* Correspondence: f.grabcanovic-musija@salk.at
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national guidelines [1]. COPD is widespread and affects
approximately 10 % of the adult population in wester-
nised countries [2]. It has substantial impact on the
quality of life and on life expectancy [3], currently being
the third leading cause of death at the global scale [4].
COPD is characterised by recurrent bacterial infection
[5, 6] along with a massive infiltration of the lung tissue
by neutrophils, even affecting airway smooth muscle [7,
8]. This makes the disease a prime candidate for the in-
volvement of neutrophil extracellular traps (NETs) in
pathogenesis. NETs are web-like extracellular structuresen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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enzymes such as neutrophil elastase (NE) and myeloper-
oxidase (MPO) that are all both antimicrobial and po-
tentially cytotoxic. They are released by activated
neutrophils, mainly in a distinct process of cell death
termed NETosis [9]. Recruitment of neutrophils into
NETosis is mediated by a variety of molecular signals
that bind to neutrophil surface receptors, among them
microbial breakdown products and the chemokine IL-8.
Reaction cascades involve the generation of reactive oxy-
gen species (ROS) by NADPH oxidase and the citrullina-
tion of histone H3 by peptidyl arginine deiminase 4
(PAD4) [10–12]. Although NETs are an important com-
ponent of innate immunity, their role is ambiguous, act-
ing between bactericidal defence and host tissue damage
[13, 14]. NETs are loaded with strongly alkaline histones
and degradative enzymes, and are associated with ROS
release and autoantibody induction by citrullinated pro-
teins. Thus they have a high cytotoxic potential, and evi-
dence is accumulating that they directly contribute to
host cell death and chronic tissue damage when formed
in excess or are insufficiently cleared by mechanisms
that are still poorly understood [15–18]. Such tissue
damage is most likely for the chronic airway diseases
cystic fibrosis (CF) and allergic asthma [19, 20] and may
therefore also affect alveolar walls in COPD. Thus, the
further clarification of the role of NETs in COPD may,
in the long term, open new therapeutic perspectives.
Until now, cessation of smoking has been the most ef-
fective intervention to slow down the decline in forced
expiratory volume per second (FEV1) and thus the pro-
gression of the disease [21]. Routine anti-inflammatory
treatment with steroids has so far been of limited suc-
cess in COPD [22], and the presence of neutrophils may
be even enhanced under steroid therapy [23].
In such context, we have recently provided new evi-
dence that the sputa of patients with exacerbated COPD
contain large amounts of NETs [24]. In the present
study, we build upon these results by testing whether (i)
excessive NET generation is restricted to the exacerba-
tion episodes of COPD or whether it also occurs during
the stable periods of the disease, and (ii) whether the
abundance of NETs correlates with the degree of airflow
limitation as measured by FEV1. Persons without airflowTable 1 Characteristics of study groups
Study group Age Sex FEV1 % predic
mean (min-max) m f mean (min-ma
Exacerbated COPD 67.5 (46–87) 11 5 32.3 (14–57)
Stable COPD 66.5 (42–74) 15 13 48.0 (23–80)
Smoking controls 47.5 (40–57) 9 8 91.1 (80–109)
Non-smoking controlsa 59.7 (41–77) 7 8 106.3 (93–129)
aNote that non-smoking controls included only one ex-smoker who stopped smokilimitation with high and low noxious exposure (smokers
and non-smokers, respectively) are used as controls.
Methods
Subjects
We examined samples of induced sputum from four
groups of subjects: (i) COPD patients with acute exacer-
bations (n = 16), (ii) COPD patients with stable disease
as seen during outpatient visits (n = 28), (iii) smoking
controls (n =17), and (iv) non-smoking controls (n = 15),
both of these controls without airflow limitation
(Table 1). Note that portions of the sputum samples
from patients with exacerbated COPD and non-smoking
controls were also utilised for our previous work charac-
terising NET micromorphology in COPD sputa as com-
pared to in vitro induced NETs [24].
COPD patients were recruited from outpatients and in-
patients seen at the University Clinic of Pneumology in
Salzburg, Austria. Smoking and non-smoking controls were
recruited through announcements in local media. When
entering the study, all subjects had their clinical history
taken and underwent physical pulmonary examination and
post-bronchodilator lung function testing according to
ATS/ERS guidelines using a Jäger bodyplethysmograph. In-
clusion criteria for participation in the study were: (i)
age over 40 years, (ii) no history of asthma. COPD was
defined on the basis of post-bronchodilator spirometry
(FEV1 < 80 % predicted and FEV1/FVC < 0.7) and a re-
ported history of current or former smoking (>10 pack-
years) according to the international guidelines [1]. These
guidelines were also applied to diagnose exacerbations. In-
clusion criteria for controls were: no signs of COPD as de-
termined by medical history, physical examination and lung
function testing (FEV1/FVC ratio > 0.7); additionally for
smoking controls: current smokers with a smoking history
of minimum 10 pack-years; additionally for non-smoking
controls: never smokers or no smoking for at least the last
ten years. Smoking controls were on average rather younger
that COPD subjects. This is because it proved impossible
to find a sufficient number of older smokers with intact
lung function (among over 100 candidate subjects that were
screened for participation in this study, we found no
smokers aged over 60 that matched the inclusion criteria).
Long-term medication of all COPD subjects was leftted GOLD grade Smoking history pack years
x) 0 I II III IV 10-40 41-70 >70
0 0 2 4 10 6 9 1
0 1 10 8 8 9 12 7
17 0 0 0 0 14 2 1
15 0 0 0 0 1 0 0
ng more than 10 years before entering the study
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ceived intravenous and oral corticosteroids (dexamethasone
and prednisolone, respectively), antibiotics, short acting
beta-agonists and short acting anticholinergics, also accord-
ing to international guidelines [1]. Smoking and non-
smoking controls did not receive any medication. Note that
evidence to date clearly indicates that anti-inflammatory
therapy with glucocorticoids (specifically dexamethasone)
has no influence on NET formation [15, 25, 26].
Ethics statement
All participants gave written informed consent before
entering the study. The study was approved by the
Ethics Committee of Salzburg Province (full German
name: Ethikkommission für das Bundesland Salzburg),
Ref. No. 415-E/1171/12-2012.
Sputum samples
Induced sputum was non-invasively collected according
to the protocols of the ECLIPSE study [8] using an Easy-
Neb™ ultrasonic nebuliser. Briefly, sputum induction
was performed by inhalation of hypertonic saline (3 %
NaCl, three times, 7 min each). Lung function tests
after each inhalation were performed with an EasyOne™
spirometer. Harvested sputa were examined for the
presence of alveolar and brochiolar epithelial cells to
ensure origin from the depth of the respiratory tract.
Sputum samples were homogenised with 0.25 mg/ml
Dithiothreitol (DTT). Depending upon subsequent use,
the sputa were adhered to either poly-D-lysine coated cov-
erslips (for immunostaining and scanning electron mi-
croscopy, 6–10 specimens from each subject in the study),
or poly-D-lysine coated strips of Aclar® fluoropolymer, or
Formvar-coated 200 mesh gold grids (both of these for
transmission electron microscopy, usable specimens from
most of the sputum samples). For comparison with DNA-
free/NET-free state, one specimen on coverslip from each
subject was treated with DNAse (2000 U/ml, 30 min, at
room temperature). All specimens were fixed in phos-
phate buffered 4 % paraformaldehyde at 4 °C. All samplesTable 2 Criteria for assessment of neutrophils and NETs in categorie
Category Predefined criteria
Non-activated neutrophil intact cell lobulated nucleus
Activated/NET-forming
neutrophil
intact cell altered nuclear
morphology
Large amounts of NETs extracellular fibrous structures positive PI-staining
Minor traces of NETs extracellular fibrous structures positive PI-staining
Classification into a category requires fulfillment of all criteria listed for that categor
from it) could apply to both neutrophil categories (‘non-activated’ and ‘activated/NE
NET-related categories because a sample was assigned to the ‘large amounts’ categ
irrespective of whether any other specimen from the same sample fulfilled only thewere assigned an anonymised code to ensure unbiased
evaluation.
Immunostaining
Immunodetection of neutrophil elastase (NE), citrulli-
nated histone H3 (CitH3), and peptidylarginine deimi-
nase 4 (PAD4) by confocal laser microscopy (CLSM)
was performed using specimens adhered to glass cover-
slips. For quantitative analysis of NET presence, ≥ 4
coverslips per subject (in most cases 6) were reacted
with rabbit anti-human NE IgG (ab21595, Abcam,
Cambridge, UK; 1:50) using propidium iodide (PI)
(P4170, Sigma Aldrich, Schnelldorf, Germany) for DNA
counterstaining. Additional specimens from many of the
subjects (from all that provided more than 4 usable cov-
erslips) were used for the parallel documentation of
NET and neutrophil morphology. These specimens were
either stained for citH3 (rabbit anti-human CitH3
(citrullin 2 + 8 + 17) IgG, Abcam ab77164; 1:50–1:100)
using PI as DNA stain, or double-stained for citH3 and
PAD4 (mouse monoclonal anti-PAD4, (Abcam ab128086;
1:100), with DAPI (Sigma-Aldrich, Germany) as DNA
stain. DNase treated control specimens were stained for
NE. DyLight®-conjugated goat anti-rabbit IgG (Abcam
ab96883; 1:100) and TRITC-labelled goat anti-mouse IgG
(Abcam ab 6786; 1:100) were used as secondary anti-
bodies. Analyses were done in a Zeiss LSM 510 meta UV
CLSM (Carl Zeiss GmbH, Vienna, Austria).
Quantitative assessment of NET and neutrophil
abundance
Specimens stained with anti-NE and PI (n ≥ 3 per tested
subject, see above) were used to evaluate the presence of
NETs and neutrophils according to four categories:
non-activated (morphologically undisturbed) neutrophils,
activated/NET-forming neutrophils, large amounts of
NETs, minor traces of NETs. All categories were assessed
in a dichotomous manner (applies or does not apply) ac-
cording to pre-defined inclusion criteria (Table 2). NETs
and NET-forming neutrophils were identified accordings
positive NE staining in
cytoplasmic granulae only
positive NE staining in
cytoplasm and/or nucleus
positive NE staining extended, confluent and/or overlapping
formations occupying at least 1 mm2
positive NE staining ≤10 small-sized (≤50 μm2) nonoverlapping
items per 100 mm2
y. Note that an individual sputum sample (and all CLSM specimens prepared
T-forming’). By contrast, an individual sputum sample could not apply to both
ory when only one CLSM specimen fulfilled the criteria for this category,
criteria for ‘minor traces’, or was free of NETs
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14, 27], and by comparison with NETs generated in vitro
from human neutrophils in our own lab [24]. NET-
forming neutrophils were identified primarily according to
their changed nuclear morphology (Table 2). Choice of
this criterion is based on the observation that loss of the
characteristic lobular form of the nucleus is a recognisable
and reliable initial morphological alteration in the NETo-
sis process, when the morphology of cytoplasm and or-
ganelles is still intact [9]. The presence of NE in the
nucleus was not used as a criterion to identify NET-
forming neutrophils because this feature is not mandatory
in the early phase of the NETosis process [24, 28].
Categories of NET abundance were classified as fol-
lows: (i) ≥ 10 small-sized (≥50 μm) non-overlapping
items per 100 mm2 coverslip surface area, mainly associ-
ated with individual neutrophils, were defined as ‘minor
traces’; (ii) extended, confluent and/or overlapping for-
mations with numerous neutrophils occupying at least
about 1 mm2 (in nearly all cases more than one quarter
of the coverslip surface) were defined as ‘large amounts’.
A patient was assigned to the large amounts group when
at least one CLSM specimen fulfilled the criteria for
“large amounts”, irrespective of whether any other speci-
men of the same patient exhibited only minor traces. Re-
sults are presented as percentages of total individuals
sampled per study group (Fig. 3a) and per COPD severity
stage (Fig. 3b). This approach was chosen as a feasible al-
ternative to methods of numerical assessment since test-
ing to adapt fluorometry-based techniques of NET
quantification applicable to in vitro use (cf./eg. [29, 30])
had failed to provide reliable results with sputa of highly
heterogeneous consistency.Morphometry-based quantification of NETs
The images of each sample used for abundance assess-
ment were also employed to provide a morphometry-
based estimation of NET quantity. The outlines of areas
covered by NET DNA were traced on red-channel (PI)
CLSM photographs and binary images of these areas
were generated using Adobe Photoshop. Non-NET DNA
(mainly intact or disintegrating nuclei of neutrophils)
was excluded. NET areas were measured with the par-
ticle analysis tool of the software ImageJ, and NET area
ratios were calculated for each sample (Figs. 3c, d).Electron microscopy
Scanning electron microscopy (SEM) served for routine
control of NET presence and was performed on speci-
mens on coverslips from most of the subjects (from all
that provided produce more than 4 usable specimens of
this kind). These were dehydrated in ethanols, critical-
point-dried with liquid CO2, sputter-coated with gold,and analysed in a ESEM XL30 (FEI Company, PHILIPS,
Eindhoven, Netherlands).
Transmission electron microscopy (TEM) was used in
two ways: (i) For the ultrastructural localisation of NE
and CitH3 within the NETs. This was done by immu-
noelectron microscopy of sputa on gold grids. Primary
antibodies were the same as described for CLSM analysis
above, 5 nm colloidal gold conjugated goat anti-rabbit
IgG (Abcam ab27235, 1:10) served as secondary anti-
body. Immunolabelled specimens were negative-stained
with uranyl acetate (1 % aqueous solution, 1 min on ice),
and (ii) for analysis of NETs and sputum components on
ultrathin sections of specimens collected on Aclar®
strips. These specimens were dehydrated in a series of
ethanols, infiltrated with Glycidether 100 (Serva) epoxy
resin via propylene oxide, and polymerised at 60 °C.
After removal of the Aclar® plastic, ultrathin sections
(80 nm) were cut on a Leica Ultracut 7 microtome,
post-stained with 0.5 % uranyl acetate and 3 % lead cit-
rate, and – as with the immunogold specimens – viewed
in a LEO EM 910. Digital images were made with a
Sharp: Eye camera system (Troendle, Moorenweis,
Germany). Specimens used for analysis were selected
from those that showed abundant NET presence in the
immunostaining results.
Statistical methods
Power calculations undertaken prior to subject recruit-
ment using the statistics software R showed that, assum-
ing a difference of at least 50 % in the presence of NETs
between patient groups and control groups, sample sizes
of 14 or higher would be adequate to detect intergroup
differences with 80 % power at the 5 % significance level
(α = 0.05).
Statistical analyses were carried out using the R pack-
age npmv (R Core 2014) [31, 32] which performs non-
parametric global multivariate analysis of variance
(MANOVA) tests. In addition to these global hypothesis
tests, the package executes a closed multiple testing pro-
cedure identifying significant differences between groups
[33]. This method allows for non-normal data and or-
dinal scales, as provided by the results of the present
study. Eight cases with missing values were deleted
(complete case analysis). In order to ensure that the
younger smoking controls (Table 1) did not introduce
bias in the inference, analyses were carried out with and
without this group (Table 3). A multiple testing proced-
ure controlling the maximum overall type 1 error (also
implemented in the R package npmv) was performed to
test for significant differences between study groups (ex-
acerbated COPD/hospitalised, stable COPD, smoking
controls, non-smoking controls) and between COPD se-
verity groups (GOLD grades 3/4, GOLD grades 1/2,
smoking controls, non-smoking controls) regarding the
Table 3 Estimated nonparametric relative effects showing intergroup differences as probabilities













Exacerbated COPD 0.27908 0.52941 0.56471 0.72680 0.75098 0.20931 0.53676 0.56225 0.75686 0.79363
Stable COPD 0.41690 0.45798 0.50280 0.49020 0.47479 0.31968 0.46534 0.50035 0.53081 0.52276
Smoking controls 0.76254 0.47794 0.50735 0.38408 0.36808
non-smoking controls 0.83725 0.52941 0.43137 0.28693 0.28431 0.74559 0.53676 0.42892 0.33137 0.32402
COPD grades 3/4 0.27669 0.51089 0.56100 0.64670 0.64089 0.20752 0.51825 0.55855 0.68192 0.68818
COPD grades 1/2 0.60784 0.41830 0.43137 0.41503 0.43682 0.47222 0.42565 0.42892 0.45425 0.47794
Smokong controls 0.76254 0.47794 0.50735 0.38408 0.36808
Non-smoking controls 0.83725 0.52941 0.43137 0.28693 0.28431 0.74559 0.53676 0.42892 0.33137 0.32402
Evaluation of study data with a closed testing procedure performing multiple hypothesis tests simultaneously, significant endpoints in bold. Summary of
estimated nonparametric relative effects of tested variables with and without inclusion of the smoking controls. Estimated relative effects measure the probability
that a value obtained from one experimental group is larger than a value randomly chosen from the whole trial including the controls. The procedure yields
similar conclusions about the significance of differences between study groups and between COPD severity groups, irrespective of whether smoking controls are
excluded or included
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or large amounts), non-activated neutrophils, activated/
NET-forming neutrophils (all ordinal), and percentage of
NET coverage in sputum preparations and FEV1 (both
continuous). Nonparametric ‘relative effects’ are pro-
vided as effect estimators. The ‘relative effects’ give an
indication of stochastic superiority, i.e. they measure the
probability that a value obtained from one experimental
group is larger than a value randomly chosen from the
whole trial including the controls. This statistical ap-
proach has been found suitable for studies aiming to
demonstrate effects that are both statistically significant
and clinically relevant [34, 35]. Spearman’s rank correl-
ation coefficient was used to assess the degree of mono-
tonic relationship between the variables FEV1 and
percentage of NET coverage.
Results
The morphological analyses using CLSM, TEM and
SEM show clearly that sputa of both patients with
acutely exacerbated COPD and patients with stable
COPD are characterised by a massive presence of NETs
and neutrophils at various stages of NET formation
(Figs. 1 and 2).
Quantitative evaluation in categories (Fig. 3a, b) pro-
vides more detailed information on this finding. It shows
that sputum samples from exacerbated COPD are most
seriously affected. They contain large amounts of NETs
and NET-forming neutrophils in more than 90 % of pa-
tients. The sputa of subjects with stable COPD, and re-
markably also those of the smoking controls without
airflow limitation, contain large amounts of NETs in
about 45 and 25 % of the patients sampled, respectively,
and NET-forming neutrophils occur in about 80 % of
each of these groups (Fig. 3a). By contrast, the sputa
from non-smoking controls were, with the exception ofone subject, either completely devoid of NETs or con-
tained them only in minor traces (Fig. 3b). The high
content of NETs in one of the control samples was most
likely caused by an asymptomatic respiratory infection
(the subject exhibited no characteristic clinical symp-
toms at the time of sampling).
These results further demonstrate that the abundance
of NET in the sputa of COPD subjects correlates with
the severity of airflow limitation. The sputum structure
of most subjects with very severe and severe COPD
(GOLD grades 4 and 3, respectively) is dominated by ex-
tended aggregates of fully spread NETs, associated with
neutrophils in various stages of NETosis. The presence
of spread NETs is also characteristic for the sputa of
subjects with moderate and mild COPD (GOLD grades
2 and 1, respectively) but with a clearly lower prevalence
as compared to grades 4 and 3. This holds also for the
presence of NET-forming neutrophils (Fig. 3b). However,
the absence of airflow limitation in the controls was only
rarely accompanied by a full absence of NETs. Indeed,
quite to the contrary, spread NETs and NET-forming
neutrophils were also characteristic of many of the con-
trol sputa, although with a clear difference between
smoking and non-smoking controls. A considerable pro-
portion of the sputa of smoking controls contained
NETs, in some cases even in large amounts. By contrast,
the sputa of non-smoking controls were (with one ex-
ception) largely free of these contents (Fig. 3a, b).
The morphometric estimation of NET content via
measurement of NET-covered area in the sputum prepa-
rations further substantiates the findings of the category-
based evaluation. Percentages of NET coverage are the
highest in patients with exacerbated COPD, those of pa-
tients with stable disease are less, followed by those of
smoking controls and non-smoking controls (Fig. 3c, d).
There is a significant negative association between the
Fig. 1 NET-forming neutrophils and NETs in sputum samples of COPD subjects stained with anti-NE (green) and PI (red). a non-activated neutrophil with
lobulated nucleus and cytoplasmic localisation of NE. (B-D) activated neutrophils at different stages of NET formation. b nucleus swollen, NE staining still
confined to cytoplasm. c NE present in both, cytoplasm and nucleus. d ruptured cell in early phase of NET release. e, f Representative examples of NET
morphology. NETs are characterised by extensive colocalisation of DNA and NE (the lack of absolute DNA-NE overlap is explainable by the irregular
molecular structure of NETs [24], and by secondary alteration this structure during sputum transport). e Long stretch of NET-DNA (arrow) extending
between two dense aggregates. In part of the motif, overlap of DNA stain and NE stain is illustrated by stippled lines. f Clusters of NET-DNA, cell debris
and an intact neutrophil (asterisk) connected by thin NET trajectories (arrows)
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airflow rate (Spearman’s rank correlation coefficient
ρ = −0.562, p < 0.00001) (Fig. 3e).
Omitting the smoking controls, global hypothesis tests
followed by a closed testing procedure show highly sig-
nificant differences between the three study groups in
the variables ‘presence of NETs’ (in large amounts or
minor traces), ‘percentage of NET-covered area’, and
‘FEV1’ (overall type 1 error rate α < 0.001). Based on this
finding, we identified these three variables as significant
endpoints (i.e. as variables that can be usefully employedto differentiate between the study groups). Exemplified for
FEV1 (the main classification criterion of COPD), the esti-
mated nonparametric relative effect for healthy controls
(i.e. the estimated probability that a randomly selected
healthy control has a larger FEV1 than a randomly se-
lected person from the whole trial including the healthy
controls) is 83.7 %. The corresponding probability esti-
mate for exacerbated COPD patients is only 27.9 % (con-
firming the simple fact that normal lung function has a
rather low probability of occurrence in exacerbated
COPD). Estimated nonparametric effects for ‘presence of
Fig. 2 Identification of NET-forming neutrophils and NETs in COPD sputum by additional methods of analysis. a-c CLSM images. a activated/NET-forming
neutrophil stained for citH3 (green) and PAD4 (red), DNA blue. b activated/NET-forming neutrophil stained for citH3 (green) and DNA (red). c Overview
image of citH3-stained specimen showing large trajectories of NET DNA intermingled with numerous activated/NET-forming and non-activated
neutrophils. The presence of citH3 and PAD4 in both the cytoplasm and the nuclei of the neutrophils conforms with the seminal study on histone
deimination in NETosis by Neeli et al. [24, 68] and with our own previous fndings on NET micromorphology [24, 68]. d-e TEM images of ultrathin
sections. d Tight attachment of NETs (arrows) to the surface of a bronchiolar epithelial cell (arrowhead) from COPD sputum; NET fibres are also
wrapped around an apparently intact (non-NET-forming) neutrophil. e Tangential section through an activated/NET-forming neutrophil outside the
nuclear region. The cell is embedded in a mass of NETs clotted with amorphous sputum substance (arrow) and contains various granulae (g), a
presumably autophagic vacuole (v), indication of vesicular traffic (arrowheads), and NET-like fibres (asterisk). f-g TEM images of on-grid immunogold
stained sputum NETs. f NE epitopes are abundant in the aggregations of organic matter along the NET fibres. g Labelling for citH3 is far less abundant
than NE stain and clustered at distinct sites of the NET meshwork. h SEM image of sputum NETs with an entangled bacterium (arrowhead)
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75.1 %, respectively, for exacerbated COPD, 49.0 and
47.5 %, respectively, for stable COPD, but only 28.7 and
28.4 %, respectively, for non-smoking controls (Table 3).
Thus, COPD patients with exacerbations have clearly
the highest probability of NETs occurring in their
sputa, distantly followed by patients with stable COPD,
irrespective of whether NETs are assessed in ordinal/di-
chotomous format or by morphometry on the sputum
preparations.
Similar to these evaluations, comparing non-smoking
controls with COPD subjects sorted by COPD severity
groups (GOLD grades 3/4 and 1/2) by the same testing
procedure as before, the variables ‘presence of NETs’,‘percentage of NET-covered area’ and ‘FEV1’ are identi-
fied as significant endpoints (overall type 1 error rate
α = 0.008).
Estimated probabilities yielded from analyses that in-
cluded the smoking controls diverge from those ob-
tained omitting these controls, but still allow similar
conclusions about the significance of intergroup differ-
ences and endpoints (Table 3).
Discussion
The present study has shown that sputa of patients with
all grades of COPD, exacerbated or stable, are charac-
terised by the presence of large amounts of NETs and
NET-forming neutrophils (Fig. 3a, b). This provides an
Fig. 3 (See legend on next page.)
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Fig. 3 Quantification of neutrophils and NETs. a, b Evaluation in categories, bars represent percentages of total individuals sampled per study
group (a) and per COPD severity stage (b). c, d Percentages of NET coverage in sputum preparations. c Bar chart showing means ± standard
errors. d Boxplots with medians and interquartile ranges, whiskers have maximum 1.5 interquartile range. Supercript asterisks indicate significant
differences between groups (P < 0.05). e Scatter plot illustrating the relation between FEV1 and the percentage of NET coverage, study groups
represented by different symbols (Spearman’s rank correlation coefficient ρ = −0.562, P < 0.001)
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in exacerbated COPD [24] and supports the assumption
that NETs also contribute to chronic inflammation in
COPD, as previously documented for a variety of other
diseases, including those of the respiratory system [17,
19, 20]. In view of the high prevalence of COPD and its
associated social burden, our findings clearly highlight
the need for further research into the role of NETosis in
COPD pathogenesis, particularly in relation to the devel-
opment of new diagnostic tools and treatment strategies.
Developing a standardised procedure of NET assessment
could provide an easily applicable and reliable means to
monitor the extent of inflammation and disease progres-
sion. Our results also add further weight to considerations
of manipulating NETosis for therapeutic purposes. Inter-
vention by local (non-systemic) application of antagonists
to neutrophil IL-8 receptors has already been identified as
a promising approach to reduce tissue damage by neutro-
phils in pulmonary disease, including CF and COPD
[36, 37]. This may now be taken further and extended to
other molecular targets (eg. inhibitors of MPO and PAD4,
and ROS scavengers) that have been recently defined as
possible therapeutics to repress NET formation [17].
Stage dependence of COPD-associated NETosis
The diagnostic and therapeutic relevance of our results
is further strengthened by the finding that COPD related
NETosis clearly correlates with the impairment of lung
function, which is considered one of the best possible in-
dicators of disease severity. All features of NETosis are
more frequently seen in the sputa of patients with exac-
erbations and at GOLD grades 3 and 4 than in those of
patients with stable COPD and at GOLD grades 1 and 2
(Fig. 3b). Together with the accumulating evidence that
NETs are potent inductors of cell and tissue damage in
inflammatory disease (eg. [15–17, 38]), these results pro-
vide initial evidence that NETosis is a harmful factor ra-
ther than a simple epiphenomenon of COPD. This
conclusion is in agreement with most recent work on
sputum NETs in CF [39], but it will certainly require
time-series studies that follow a particular cohort of pa-
tients to obtain further verification and to examine pro-
gression over time.
NET forming neutrophils, in contrast to apoptotic
cells, were found to lack signals inducing their clear-
ance by phagocytes [17]. NETosis is able to function in
self-perpetuating cycles, driving the process into adetrimental excess (eg. [40]), particularly in situations
of non-microbial induced (sterile) inflammation (eg.
[25, 41, 42]). The massive presence of NETs in the
sputa of COPD patients (Figs. 1, 2 and 3) may indicate
exactly such an over-reactive response beyond the re-
quirements of anti-microbial defence. This interpret-
ation is consistent with the experience from patients
with CF [19], and with the conclusion on adverse NET
effects in a variety of other inflammatory lung diseases
in the recent literature [43]. It is also in agreement with
recent in vitro evidence of variants of the NETosis
mechanism that are faster than the standard type.
These mechanisms are activated in response to bacter-
ial challenge and may be most appropriate for a role in
lung defence. This holds particularly for a mechanism
mediated by immunoglobulin A, the predominant anti-
body to provide mucosal protection against pathogens
[44], but also for a second mechanism that leaves neu-
trophils after NET extrusion viable and phagocytotically
active [29]. In the light of the present results it would
be important to test whether these NETosis mecha-
nisms are active in COPD.
Our observation that NETs are present in patients
with exacerbated COPD even though they were treated
with systemic corticosteroids is in agreement with recent
experimental evidence that such medication is insuffi-
cient to reduce NET formation [25, 26]. Furthermore,
detrimental effects of NETs in COPD lungs may not be
confined to direct damage to the epithelia [45], but may
also include indirect damage via promotion of auto-
immune reactions against NET components (cf. [46]).
Together, this could be a relevant contribution to the
fatal spiral of decline in lung function that characterises
the progression of COPD. Self-perpetuating NETosis
may also help to explain why COPD subjects exhibit
persistent airway inflammation and even increased num-
bers of sputum neutrophils after one year of cessation of
smoking [21]. However, COPD has been recently de-
scribed as a heterogeneous disease with a non-uniform
lung function decline [47]. It therefore remains to be
established whether individual disposition to NETosis is
relevant to understand the different COPD phenotypes.
Implication of COPD-associated NETosis for tumour
development
NETosis is an important mechanism to enhance oxida-
tive stress, not least through the abundant release of
Grabcanovic-Musija et al. Respiratory Research  (2015) 16:59 Page 10 of 12myeloperoxidase (MPO) [28, 48], a potent generator of
potentially tissue harming oxidants [49–51]. In view of
the well established close relationship between oxidative
stress, chronic inflammation, and cancer (e.g. [52–54]),
it would appear worthwhile to explore whether routine
measurement of sputum NETs could aid tumour risk as-
sessment and tumour prevention in COPD.
Smoking and non-smoking controls
Further indication that NETosis may be a potentially
harmful factor in the development of COPD is provided
by the finding that NETs are not only abundant in the
sputa of subjects with COPD, but also in those of a pro-
portion of smokers who do not exhibit airflow limitation
(Fig. 3a-d). It is well established that in westernised
countries, smokers constitute the main candidate popu-
lation to develop COPD [47, 55]. The results of the
present work could indicate that cigarette smoke-induced
NETosis commits some smokers into a self-perpetuating
cycle of inflammation and respiratory damage, eventually
terminating in full scale COPD. Known variation among
smokers in their risks of developing COPD (average about
50 %) is well documented [56, 57] and may be directly
reflected in the high presence of NETs in the sputa of
some of the smoking controls (Fig. 3). A pathological rele-
vance of the high presence of NETs in the sputa of the
smokers is supported by the fact that the difference be-
tween the smokers and the stable COPD group is not pro-
nounced (Fig. 3c, d). This has alarming implications just
because the smokers group is on average younger: previ-
ous work demonstrates that neutrophil recruitment in the
lung, the key requisite of NET formation, increases with
age, even in healthy subjects [58]. A negative influence of
NET presence in the lungs of smokers is also supported
by our observations when searching for participants in the
study. Not only that we could not find smokers over 60
with sufficient lung function, but even some of those
screened that were clearly younger (at around 40) had a
considerable impairment and were thus diagnosed with
COPD for the first time.
All this is in agreement with the accumulating evi-
dence that commitment to NETosis depends on the
interplay between the inducing external factors and the
intrinsic genetic framework of the individual host [59].
This interplay may also aid in understanding the rather
surprising presence of NET traces in about 20 % of the
samples from non-smoking controls, and the presence
of activated/NET-forming neutrophils in almost 70 % of
these control samples (Figs. 2 and 3). Whether this indi-
cates a short term low-level (‘routine’) employment of
NETosis in pulmonary antimicrobial defence, or involves
a side effect of sputum induction (see below), remains to
be tested. Neutrophil recruitment into alveolar spaces
may be regarded as an established contributor to normalphagocytotic clearance of inhaled bacteria and organic
dust (eg. [60, 61]). The underlying molecular regulation
and interplay with macrophages has been clarified over
recent years [62–64].
Possible bias from sputum induction
On the basis of the present literature, it cannot be en-
tirely ruled out that sputum induction according to
protocol of the ECLIPSE study [8] leads to the formation
of additional NETs. Previous work has found that spu-
tum induction can evoke a short-lived neutrophilic re-
sponse and may also exert prolonged inflammatory
stimuli, especially when repeatedly applied (e.g. [65]).
However, there is also evidence that the effect is not ex-
cessive, even in patients with COPD [66] and influences,
within the time required for sputum acquisition, neutro-
phil content rather than NET content. The ECLIPSE
study itself mentions that sputa from healthy airways in-
duced by this method contain intact neutrophils. This is
in agreement with our results from non-smoking con-
trols (Fig. 3a, b). The low presence of NETs in these con-
trol sputa, on the other hand, supports the view that the
effect of sputum induction on the NET content of the
harvested sputa is limited. This appears even more
plausible as it takes clearly more than one hour until ac-
tivated neutrophils are ready to release NETs [67]. The
extreme difference in NET content that is apparent be-
tween these controls and the sputa of the COPD sub-
jects (Fig. 3a-c) suggests that the mass of NETs found in
the latter results from the disease and not from sputum
induction.
Conclusions
From the results of this work we conclude that (i) NETs
are the dominant (if not exclusive) source of sputum DNA
in COPD, (ii) In view of the accumulating evidence of
NET-mediated tissue damage from a variety of chronic in-
flammatory diseases including such of the lung (eg. [43]),
NETs could contribute to lung function decline in a high
proportion of the patients with COPD, (iii) this detrimen-
tal development may already be initiated in smokers with-
out airflow limitation, (iv) NET recruitment at very low
levels is a component of normal lung defence, and that (v)
routine assessment of the NET burden could help to opti-
mise the effective use of medication (e.g. the application
of steroids [22, 23]), and tumour risk assessment and
tumour prevention in COPD.
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